Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829737 · ClinicalTrials.gov registry record
Malaria Transmission Studies in Mali
A clinical trial of Malaria, Falciparum, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 534
- Enrollment target
- 1
- Study location
NCT01829737 is a study of Malaria, Falciparum that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 534 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01829737, a study of Malaria, Falciparum, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 534 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person. Not everyone infected with parasites have gametocytes in their blood. As a result, not everyone can spread malaria to others. Researchers are interested in learning more about why some healthy people have gametocytes in their blood and others do not. Identifying the people who have gametocytes in their blood can help target treatment and reduce the spread of malaria. This study will focus on the people of the village of Kenieroba in Mali, where malaria is common. Objectives: \- To study the relationship between gametocytes and malaria transmission in Mali. Eligibility: \- Individuals between 6 months and 65 years of age who live in Kenieroba, Mali, and will stay in the area for 1 year. Design: * For 1 year, participants will have study visits once every 2 weeks (twice a month, for a total of 24 visits). The visits will last 30 minutes each. * At each visit, participants will provide a small blood sample. They will report any symptoms of malaria such as fever, headache, and body aches. Participants will be encouraged to seek medical treatment if they experience malaria symptoms between visits. * Participants who have malaria symptoms will have a blood test for malaria parasites. Those who have parasites in the blood will receive antimalarial treatment. * Three times over 1 year, a larger blood sample will be collected. These blood samples will be taken once in the dry season, once in the wet season, and once in the next dry season. * Women between 14 and 45 years of age will also provide urine samples to test for pregnancy. Pregnant women will not be asked to give blood samples.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2013-03-20 |
| Est. Completion | 2015-01-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829737
The ClinicalTrials.gov registry entry for NCT01829737 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 534 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malaria, Falciparum appearing as the primary indexed condition, and to 0 interventions.
NCT01829737 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01829737 about?
NCT01829737 is a clinical study titled "Malaria Transmission Studies in Mali". Background: \- Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person. Not everyone infected with parasites have gametocytes in their blood. As ...
What is the current status of trial NCT01829737?
This trial is currently completed. The enrollment target is 534 participants. The study started on 2013-03-20. Estimated completion is 2015-01-20.
What conditions does trial NCT01829737 study?
This clinical trial studies the following conditions: Malaria, Falciparum.
Who is sponsoring clinical trial NCT01829737?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01829737 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria, Falciparum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.